View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
February 18, 2020updated 04 Sep 2020 7:20am

China approves first anti-viral drug against coronavirus Covid-19

Anti-viral drug Favilavir has secured approval from the National Medical Products Administration of China to treat coronavirus Covid-19, according to media reports.


Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates

Free Report
img

Navigate your business through the ‘new normal’

COVID-19 continues to dominate headlines the world over. It has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities.  Faced with an explosion of conflicting information on how to plan and implement successful recovery strategies, decision-makers are in dire need of a single, reliable source of intelligence.   GlobalData’s COVID-19 Executive Briefing gives you access to unparalleled data and insights to successfully navigate the uncertain road to recovery across the world’s largest industries. Understand every aspect of this disruptive theme by delving into: 
  •  COVID-19 infection update, with statistics on the spread, testing by country, as well as the latest data on vaccines and therapeutic developments 
  • Economic impact overview, covering stock market indices, GDP, unemployment rates, policy responses & GlobalData’s economic recovery scorecards 
  • Sector developments, with access to sector insight summaries, cross-sector indices and the leaders and laggards in each industry vertical 
Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today. 
by GlobalData
Enter your details here to receive your free Report.

Follow the latest updates of the outbreak on our timeline.

Anti-viral drug Favilavir has secured approval from the National Medical Products Administration of China to treat coronavirus Covid-19, according to media reports.

China Daily reported that the Taizhou government in Zhejiang province announced the approval, which marks the authorisation of the first drug against the new coronavirus.

Formerly Fapilavir, the drug was developed by Zhejiang Hisun Pharmaceutical.

Fapilavir allegedly demonstrated efficacy with minor side effects in an ongoing 70-patient clinical trial in Shenzhen, Guangdong province. The drug’s generic version received the approval.

Production of the anti-viral drug was begun on Sunday, added the news agency.

According to China’s Ministry of Science and Technology, Favilavir is one of the three drugs that showed encouraging profile for blocking the new coronavirus in early clinical trials.

The remaining two drugs are anti-malaria drug chloroquine and Gilead’s experimental drug remdesivir.


See all Coronavirus vaccines and drugs in the pipeline


Chloroquine, an existing medicine, is under assessment in more than 100 patients at over ten hospitals in Beijing and Guangdong province. Plans for an additional study in Hunan province are underway.

Meanwhile, Gilead’s drug is said to be in studies at more than ten medical institutions in Wuhan, the epicentre of the Covid-19 outbreak.

A study by the US National Institutes of Health (NIH) revealed that remdesivir could prevent the Middle East respiratory syndrome coronavirus (MERS-CoV), a type of coronavirus in monkeys, offering hope for China trials.

Earlier this month, the Wuhan Institute of Virology filed an application seeking a new patent on remdesivir.

Related Companies

Free Report
img

Navigate your business through the ‘new normal’

COVID-19 continues to dominate headlines the world over. It has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities.  Faced with an explosion of conflicting information on how to plan and implement successful recovery strategies, decision-makers are in dire need of a single, reliable source of intelligence.   GlobalData’s COVID-19 Executive Briefing gives you access to unparalleled data and insights to successfully navigate the uncertain road to recovery across the world’s largest industries. Understand every aspect of this disruptive theme by delving into: 
  •  COVID-19 infection update, with statistics on the spread, testing by country, as well as the latest data on vaccines and therapeutic developments 
  • Economic impact overview, covering stock market indices, GDP, unemployment rates, policy responses & GlobalData’s economic recovery scorecards 
  • Sector developments, with access to sector insight summaries, cross-sector indices and the leaders and laggards in each industry vertical 
Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today. 
by GlobalData
Enter your details here to receive your free Report.

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU